DEF 14A: Oramed Pharmaceuticals Sets Date for Annual Stockholders Meeting, Director Re-Election and Executive Compensation on the Agenda

Oramed Pharmaceuticals will hold its annual meeting of stockholders on August 1, 2024, to vote on director re-elections, executive compensation, and auditor ratification.

Summary

• Oramed Pharmaceuticals Inc. will hold its Annual Meeting of Stockholders on August 1, 2024, in Jerusalem.
• Stockholders of record as of June 12, 2024, are entitled to vote.
• The meeting will address the re-election of seven directors, an advisory vote on executive compensation, and the ratification of Kesselman & Kesselman as the independent auditor for the 2024 fiscal year.
• The Board of Directors recommends voting FOR all proposals.
• The company intends to first mail the proxy statement and annual report to stockholders on or about June 19, 2024.
• As of June 12, 2024, there were 40,628,924 shares of common stock outstanding and entitled to vote.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The company is following standard corporate governance procedures, which is a positive sign.

Positives

• The Board of Directors is committed to continuous improvement and conducts a board and committee evaluation process each year.
• The Audit Committee has recommended that the audited financial statements be included in the Annual Report on Form 10-K for Fiscal 2023 for filing with the SEC.
• The Compensation Committee believes that the executive compensation is appropriately designed to incentivize the NEOs to work for the company's long-term prosperity.
• Stockholders approved, on an advisory basis, the executive compensation program at the annual meeting of stockholders held on June 30, 2022, with approximately 90% of the total stockholders votes cast in favor.

Negatives

• Directors and officers failed to timely file a Form 4 reporting their annual equity grants granted on April 17, 2023, due to a technical issue, although the forms were filed shortly after on April 20, 2023.
• David Silberman resigned from his positions with the Company for personal reasons, originally effective as of July 12, 2024 (as modified when Mr. Avraham Gabay was appointed as described below).

Risks

• The proxy statement does not explicitly detail any specific risks facing the company.
• The company's success depends on the re-election of key directors and the approval of executive compensation plans.

Future Outlook

The document outlines the agenda for the upcoming Annual Meeting of Stockholders, focusing on governance matters such as director elections and executive compensation. It does not provide specific forward-looking statements about the company's financial performance or business prospects beyond the meeting itself.

Management Comments

• Nadav Kidron, President, Chief Executive Officer and Director: 'You are cordially invited to attend the Annual Meeting of Stockholders'.
• The Board unanimously recommends that you vote FOR all of the above proposals.

Industry Context

Proxy statements are standard documents for publicly traded companies, providing transparency and enabling shareholder participation in corporate governance. The items to be voted on are typical for such meetings.

Comparison to Industry Standards

• The peer group of companies used for compensation benchmarking includes ALX Oncology Holdings Inc., Anavex Life Sciences Corp., Arbutus BioPharma Corporation, Atossa Therapeutics Inc., aTyr Pharma, Inc., Chimerix, Inc., Compugen Ltd., Fulcrum Therapeutics, Inc., Gamida Cell Ltd., Immunic, Inc., Lyra Therapeutics, Inc., Marinus Pharmaceuticals, Inc., MediciNova, Inc., Minerva Neurosciences, Inc., Rani Therapeutics, Inc., Relmada Therapeutics, Inc., Vistagen Therapeutics, Inc. and Zevra Therapeutics, Inc..
• These companies are used to provide a competitive compensation benchmark for Oramed's management.

Management Changes

Stakeholder Impact

• Shareholders will have the opportunity to vote on key governance matters.
• The outcome of the votes will influence the composition of the Board of Directors and executive compensation.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting of Stockholders on August 1, 2024.
• The company will file a report on Form 8-K with the SEC to announce the final voting results within four business days after the Annual Meeting.

Key Dates

Keywords

proxy statement, annual meeting, directors, executive compensation, auditor, stockholders, Oramed Pharmaceuticals